Skip to main content
VERA
NASDAQ Life Sciences

FDA Aligns with Vera Therapeutics on Accelerated Atacicept Approval Pathway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$34.31
Mkt Cap
$2.436B
52W Low
$18.79
52W High
$56.05
52W Position info
83% above low
Off High info
39% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

VERA sits 83% above its 52-week low of $18.79.

Summary

Vera Therapeutics announced FDA alignment on an accelerated timeline for atacicept's eGFR results and sBLA submission, moving up potential full approval for its IgA Nephropathy treatment.


Key Events · Product Development and Regulatory · VERA

  • FDA Alignment for Atacicept

    Vera Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in adults with IgA Nephropathy.

  • Accelerated Timeline for Results

    The eGFR results are now expected in the third quarter of 2026, an earlier timeline than previously anticipated.

  • Path to Full Approval

    Pending these results, the company plans to submit a supplemental Biologics License Application (sBLA) for full approval of atacicept in the fourth quarter of 2026.


Analysis · VERA · Life Sciences

Vera Therapeutics has secured alignment with the FDA on an earlier analysis plan for atacicept's ORIGIN 3 eGFR results, which are now expected in Q3 2026. This accelerates the potential submission of a supplemental Biologics License Application for full approval in Q4 2026, providing a clearer and faster path to market for its key IgA Nephropathy drug. This positive regulatory update for a lead candidate is a significant development for the company.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERA was trading at $34.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.79 to $56.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERA - Latest Insights

VERA
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $29.53
Real-time Price: $24.88 info
Change: -$4.65 (-16%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.07
Real-time Price: $24.88 info
Change: -$6.19 (-20%) info
Market Cap: $1.84B info
VERA
Nov 05, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $30.98
Real-time Price: $24.88 info
Change: -$6.10 (-20%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.64
Real-time Price: $24.88 info
Change: -$13.76 (-36%) info
Market Cap: $1.84B info
VERA
Sep 15, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $37.69
Real-time Price: $24.88 info
Change: -$12.81 (-34%) info
Market Cap: $1.84B info